Skip to content

US · RNAZ · BIOTECHNOLOGY

TransCode Therapeutics, Inc. (RNAZ) intrinsic value and stock valuation

$1.16as of 2026-11-21 · Mkt cap 4.5M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

TransCode Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values RNAZ with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from RNAZ’s statements →

TransCode Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Boston, MA 02109 transcodetherapeutics.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$0.00
20182025
Net income
-$-34.66M
20182025
Free cash flow
-$-19.52M
20182025
Total equity
$10.3M
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-27.98M-$-15.66M-$-19.42M-$-18.67M-$-6.15M
Net income-$-34.66M-$-16.75M-$-18.55M-$-17.56M-$-6.84M
EPSd-$-50.23M-$-46.53M-$-1.86B-$-878M-$-684M
Operating cash flow-$-19.52M-$-13.34M-$-18.07M-$-15.76M-$-5.27M
Capital expenditure-$-10K-$-20K-$-40K-$-100K-$-250K
Free cash flow-$-19.52M-$-13.36M-$-18.11M-$-15.86M-$-5.52M
Total assets$162.4M$7.29M$5.17M$7.59M$22.9M
Total debt$0.00$40K$450K$0.00$0.00
Net debt-$-17.81M-$-5.77M-$-2.32M-$-4.97M-$-20.83M
Total equity$10.3M-$-2.02M$1.64M$3.24M$20.4M
Cash and short-term investments$17.8M$5.81M$2.77M$4.98M$20.8M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$530K$520K$100K$40K
Gross profit$0.00-$-530K-$-520K-$-100K-$-40K
Research and development expenses$13.4M$9.62M$12.3M$10.2M$2.75M
Selling, general and administrative expenses$5.77M$5.51M$6.64M$8.33M$3.35M
Other expenses$8.79M$0.00$0.00$0.00$0.00
Operating expenses$28M$15.1M$18.9M$18.6M$6.11M
Cost and expenses$28M$15.7M$19.4M$18.7M$6.15M
Interest income$80K$0.00$10K$20K$0.00
Interest expense$10K$30K$60K$17.6M$100K
Depreciation and amortization$110K$530K$520K$100K$40K
Ebitda-$-34.31M-$-16.19M-$-17.97M-$-17.47M-$-6.71M
Operating income-$-27.98M-$-15.66M-$-19.42M-$-18.67M-$-6.15M
Total other income/expenses, net-$-6.45M-$-1.09M$870K$1.1M-$-690K
Income before tax-$-34.44M-$-16.75M-$-18.55M-$-17.56M-$-6.84M
Income tax expense$230K$0.00$0.00$0.00$0.00
Net income-$-34.66M-$-16.75M-$-18.55M-$-17.56M-$-6.84M
Weighted average shares outstanding$690K$360K$10K$20K$10K
Weighted average diluted shares outstanding$690K$360K$10K$20K$10K
Balance sheet
20252024202320222021
Cash and short-term investments$17.8M$5.81M$2.77M$4.98M$20.8M
Net receivables$3.25M$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$22M$7.09M$4.46M$7.38M$22.7M
Property, plant and equipment, net$370K$90K$600K$210K$210K
Goodwill and intangible assets$140M$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$140.4M$200K$710K$210K$210K
Total assets$162.4M$7.29M$5.17M$7.59M$22.9M
Accounts payable$3.12M$2.58M$0.00$0.00$2.02M
Short-term debt$0.00$40K$410K$0.00$0.00
Deferred revenue$0.00$0.00$30K$0.00$30K
Total current liabilities$3.49M$2.77M$3.49M$4.35M$2.53M
Long-term debt$0.00$0.00$40K$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$148.6M$6.54M$40K$0.00$0.00
Capital lease obligations$0.00$0.00$450K$0.00$0.00
Total liabilities$152.1M$9.31M$3.53M$4.35M$2.53M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-97.86M-$-63.2M-$-46.42M-$-27.87M-$-10.31M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$10.3M-$-2.02M$1.64M$3.24M$20.4M
Total investments$0.00$0.00$0.00$10K$0.00
Total debt$0.00$40K$450K$0.00$0.00
Net debt-$-17.81M-$-5.77M-$-2.32M-$-4.97M-$-20.83M
Cash flow statement
20252024202320222021
Net income-$-34.66M-$-16.75M-$-18.55M-$-17.56M-$-6.84M
Depreciation and amortization$110K$530K$520K$100K$40K
Stock-based compensation$490K$1.7M$0.00$400K$190K
Change in working capital$20K-$-350K-$-1.08M$1.31M$430K
Accounts receivable-$-950K$0.00$360K-$-360K$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00-$-1.3M$1.84M$2.29M
Net cash provided by operating activities-$-19.52M-$-13.34M-$-18.07M-$-15.76M-$-5.27M
Investments in property, plant and equipment-$-10K-$-20K-$-40K-$-100K-$-250K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$0.00-$-20K-$-40K-$-100K-$-250K
Common stock issued$8.85M$16.4M$15.9M$10K$26.3M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$31.5M$16.4M$15.9M$10K$25.5M
Net change in cash$12M$3.04M-$-2.2M-$-15.86M$20M
Cash at end of period$17.8M$5.81M$2.77M$4.97M$20.8M
Operating cash flow-$-19.52M-$-13.34M-$-18.07M-$-15.76M-$-5.27M
Capital expenditure-$-10K-$-20K-$-40K-$-100K-$-250K
Free cash flow-$-19.52M-$-13.36M-$-18.11M-$-15.86M-$-5.52M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About TransCode Therapeutics, Inc.

        TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidate, the company's preclinical portfolio also features TTX-siPDL1, an siRNA designed to modulate programmed death-ligand 1, and TTX-siLIN28B, another siRNA that inhibits the RNA-binding protein LIN28B. TransCode also pursues several cancer-agnostic initiatives. These encompass TTX-RIGA, an RNA-based agent engineered to stimulate the RIG-I immune pathway within the tumor's immediate surroundings; TTX-CRISPR, a gene-editing platform utilizing CRISPR/Cas9 technology to correct or eradicate oncogenic genes within cancer cells; and TTX-mRNA, an innovative mRNA platform dedicated to creating cancer vaccines that incite powerful cytotoxic immune reactions against malignant cells. Established in 2016, TransCode Therapeutics is headquartered in Boston, Massachusetts.

        CEO
        Philippe Calais
        Employees
        12
        Beta
        1.24

        Explore

        Frequently asked questions

        What is the intrinsic value of TransCode Therapeutics, Inc. (RNAZ)?

        InvestorsCraft does not currently publish an intrinsic value for RNAZ. How the IC value is calculated.

        Is RNAZ undervalued?

        InvestorsCraft does not publish an undervaluation signal for RNAZ at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.